Actively Recruiting
Intralesional Therapies For Cutaneous Viral Warts: A Comparative Analysis Of Vitamin D3 And Acyclovir
Led by Riphah International University · Updated on 2026-03-10
40
Participants Needed
2
Research Sites
N/A
Total Duration
On this page
AI-Summary
What this Trial Is About
This clinical trial studies whether injecting acyclovir or vitamin D3 directly into skin warts helps clear them in people aged 12 and older who have common, plantar, flat, or periungual warts. It aims to find out if either treatment leads to complete wart clearance by week 8, which treatment works better, and what side effects occur. The trial is a Phase 4 study comparing two treatment groups with 20 participants each. Participants receive injections of either acyclovir or vitamin D3 into the wart every two weeks for up to four sessions. The dose varies by wart size, with injections given at the start and repeated biweekly. Both treatments are delivered directly into the wart lesion. This comparison helps researchers evaluate the effectiveness and safety of these two intralesional therapies. During the study, participants will have photographs taken of their warts before treatment and at every visit. Clinic visits include measuring the size and number of warts. After treatment, participants are followed for up to three months to monitor wart recurrence and any side effects. The main outcome measured is wart clearance at week 8, with additional tracking of early recurrence, adverse effects, and number of treatment sessions needed.
CONDITIONS
Brief Title
Intralesional Therapies For Cutaneous Viral Warts: A Comparative Analysis Of Vitamin D3 And Acyclovir
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients aged 12 years and above with clinically diagnosed cutaneous warts
- Common, plantar, flat, or periungual warts
- Both treatment-nafve patients and those with recalcitrant warts
You will not qualify if you...
- Pregnant or lactating women
- Immunocompromised patients
- Individuals with history of hypersensitivity to vitamin D3 or acyclovir
- Individuals receiving systemic immunosuppressive or antiviral therapy
- Patients with secondary infection at injection site
- Patients who had received any topical or destructive treatment for wart in previous three months
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Up to 8 weeks
Participants receive intralesional injections of either acyclovir or vitamin D3 directly into the wart lesion. Injections are administered at baseline and repeated every 2 weeks for up to four sessions.
Up to 4 visits every 2 weeks
Duration - Up to 3 months from baseline
Participants are monitored for early recurrence of warts and adverse effects of treatment.
Visits as scheduled during follow-up period
Trial Site Locations
Total: 2 locations
1
Railway General Hospital, Railway Carriage Factory Rd, Railway Scheme 7, Rawalpindi
Rawalpindi, Punjab Province, Pakistan, 46000
Actively Recruiting
2
Riphah International Hospital, Islamabad Expy, Sector A DHA Phase 5, Islamabad
Islamabad, Pakistan, 44000
Actively Recruiting
How is the study designed?
Study Type
INTERVENTIONAL
Masking
SINGLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here